BR112014017969A8 - Microesferas ou micropartículas bioerodíveis ou bio-degradáveis liberadas por tempo suspensas em uma formulação de droga injetável de formação de depósito - Google Patents

Microesferas ou micropartículas bioerodíveis ou bio-degradáveis liberadas por tempo suspensas em uma formulação de droga injetável de formação de depósito

Info

Publication number
BR112014017969A8
BR112014017969A8 BR112014017969A BR112014017969A BR112014017969A8 BR 112014017969 A8 BR112014017969 A8 BR 112014017969A8 BR 112014017969 A BR112014017969 A BR 112014017969A BR 112014017969 A BR112014017969 A BR 112014017969A BR 112014017969 A8 BR112014017969 A8 BR 112014017969A8
Authority
BR
Brazil
Prior art keywords
deposit
bioerodible
drug formulation
microparticles
injection drug
Prior art date
Application number
BR112014017969A
Other languages
English (en)
Other versions
BR112014017969A2 (pt
Inventor
A Marsh David
Ma Rivers Hongwen
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112014017969A2 publication Critical patent/BR112014017969A2/pt
Publication of BR112014017969A8 publication Critical patent/BR112014017969A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MICROESFERAS OU MICROPARTÍCULAS BIOERODÍVEIS OU BIODEGRADÁVEIS LIBERADAS POR TEMPO SUSPENSAS EM UMA FORMULAÇÃO DE FÁRMACO INJETÁVEL DE FORMAÇÃO DE DEPÓSITO. Um material compósito de distribuição de fármaco pode ser injetado no olho de um ser humano ou mamífero para fornecer distribuição sustentada do fármaco. Um material compósito de distribuição de fármaco pode incluir uma pluralidade de micropartículas dispersas em uma composição de meios. As micropartículas podem conter um fármaco e um revestimento compreendendo um material bioerodível ou um material biodegradável, e a composição de meios inclui o fármaco dispersado em um material de formação de depósito. A composição de meios pode se tornar gel ou solidificar após injeção dentro do olho.
BR112014017969A 2012-01-23 2013-01-22 Microesferas ou micropartículas bioerodíveis ou bio-degradáveis liberadas por tempo suspensas em uma formulação de droga injetável de formação de depósito BR112014017969A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261589681P 2012-01-23 2012-01-23
PCT/US2013/022466 WO2013112434A1 (en) 2012-01-23 2013-01-22 Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation

Publications (2)

Publication Number Publication Date
BR112014017969A2 BR112014017969A2 (pt) 2017-06-20
BR112014017969A8 true BR112014017969A8 (pt) 2017-07-11

Family

ID=47630595

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017969A BR112014017969A8 (pt) 2012-01-23 2013-01-22 Microesferas ou micropartículas bioerodíveis ou bio-degradáveis liberadas por tempo suspensas em uma formulação de droga injetável de formação de depósito

Country Status (18)

Country Link
US (3) US20130189369A1 (pt)
EP (1) EP2806853B1 (pt)
JP (1) JP6282231B2 (pt)
KR (5) KR20140114892A (pt)
CN (1) CN104136006B (pt)
AU (3) AU2013212583A1 (pt)
BR (1) BR112014017969A8 (pt)
CA (1) CA2861348C (pt)
DK (1) DK2806853T3 (pt)
ES (1) ES2821526T3 (pt)
HK (1) HK1204765A1 (pt)
HU (1) HUE050904T2 (pt)
IL (2) IL233620A0 (pt)
MX (1) MX364864B (pt)
NZ (1) NZ627368A (pt)
RU (1) RU2672596C2 (pt)
WO (1) WO2013112434A1 (pt)
ZA (1) ZA201405091B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150335704A1 (en) * 2014-05-23 2015-11-26 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
US20170112936A1 (en) * 2014-05-23 2017-04-27 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
CN104306330A (zh) * 2014-09-24 2015-01-28 万特制药(海南)有限公司 一种盐酸美金刚缓释混悬液及其制备方法
FI3352735T3 (fi) 2015-09-21 2023-10-20 Teva Pharmaceuticals Int Gmbh Pitkitetysti vapauttavia olantsapiiniformulaatioita
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
CA2972296A1 (en) * 2016-06-30 2017-12-30 Durect Corporation Depot formulations
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
EP3651800B1 (en) * 2017-07-11 2024-04-10 Sustained Nano Systems LLC Hypercompressed pharmaceutical formulations
CN107595765A (zh) * 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送系统及其制备方法
GB2586975B (en) * 2019-09-09 2024-03-06 Roemex Ltd Device and method for use with subsea pipelines
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
WO2022198167A1 (en) * 2021-03-15 2022-09-22 Oakwood Laboratories, Llc Microsphere formulations comprising naltrexone and methods for making and using the same
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
KR100374098B1 (ko) * 1994-04-08 2003-06-09 아트릭스 라보라토리스, 인코포레이션 조절된방출이식편형성에적합한액체전달조성물
EP0959873B1 (en) * 1996-12-20 2006-03-01 ALZA Corporation Gel composition and methods
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
CN1314452C (zh) * 2002-04-22 2007-05-09 沈阳药科大学 具有适宜相转变温度的眼用原位凝胶制剂
CN100453066C (zh) * 2002-12-04 2009-01-21 参天制药株式会社 利用结膜下储存库的药物释放系统
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
UA96342C2 (en) * 2007-06-25 2011-10-25 Оцука Фармасьютикал Ко., Лтд. Microspheres having core/shell structure
EP2482804A1 (en) * 2009-10-01 2012-08-08 Evonik Degussa Corporation Microparticle compositions and methods for treating age-related macular degeneration
CN101816627B (zh) * 2010-04-16 2012-03-07 浙江大学 一种协同治疗型多物质缓释滴眼剂及制备方法
CN102100663B (zh) * 2011-01-14 2013-04-17 华南理工大学 一种pH敏感型原位凝胶纳米缓释眼药水的制备方法

Also Published As

Publication number Publication date
JP2015504098A (ja) 2015-02-05
KR20220044379A (ko) 2022-04-07
ZA201405091B (en) 2015-12-23
AU2013212583A1 (en) 2014-08-14
US20130189369A1 (en) 2013-07-25
KR102183727B1 (ko) 2020-11-27
HK1204765A1 (en) 2015-12-04
CN104136006B (zh) 2017-11-24
CA2861348A1 (en) 2013-08-01
KR20200073292A (ko) 2020-06-23
AU2019204957A1 (en) 2019-07-25
BR112014017969A2 (pt) 2017-06-20
JP6282231B2 (ja) 2018-02-21
RU2672596C2 (ru) 2018-11-16
KR20230104761A (ko) 2023-07-10
MX2014008857A (es) 2015-07-17
IL265620B (en) 2022-03-01
AU2017258895A1 (en) 2017-11-30
AU2017258895B2 (en) 2019-04-18
CA2861348C (en) 2017-07-04
IL265620A (en) 2019-05-30
MX364864B (es) 2019-05-09
US20230390212A1 (en) 2023-12-07
KR20140114892A (ko) 2014-09-29
EP2806853B1 (en) 2020-07-08
IL233620A0 (en) 2014-08-31
WO2013112434A1 (en) 2013-08-01
CN104136006A (zh) 2014-11-05
RU2014134420A (ru) 2016-03-20
KR20200133286A (ko) 2020-11-26
EP2806853A1 (en) 2014-12-03
ES2821526T3 (es) 2021-04-26
US20200297650A1 (en) 2020-09-24
DK2806853T3 (da) 2020-09-28
NZ627368A (en) 2016-11-25
HUE050904T2 (hu) 2021-01-28

Similar Documents

Publication Publication Date Title
BR112014017969A8 (pt) Microesferas ou micropartículas bioerodíveis ou bio-degradáveis liberadas por tempo suspensas em uma formulação de droga injetável de formação de depósito
BR112013032469A2 (pt) composição, método de sintetização de micropartículas de fumaril diquetopiperazina, método de entrega de insulina para um paciente com necessidade do mesmo e micropartícula de diquetopiperazina
PH12016500691A1 (en) Smoking article with liquid release component
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
BR112014019750A2 (pt) composto, composlção farmacêutlca, método para aumentar a lnclusão de éxon 7 de smn2 em mrna, método para aumentar a quantidade de proteína smn e método para tratar sma em um indivíduo humano em necessidade
CL2014002956A1 (es) Composicion farmaceutica ocular que comprende particulas recubiertas de dimension menor a 1 micron, con un nucleo que comprende etaboato de loteprednol y un recubrimiento con modificadores de superficie; y uso para tratar la inflamacion, degeneracion macular, edema macular u otro trastorno del ojo.
ECSP10010684A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad.
MX352369B (es) Articulo para fumar con material de entrega de liquido.
EP2925340B8 (en) Pharmaceutical compositions comprising selective agonists of melanocortin 1 receptor and their use in therapeutic methods
BR112012014904A2 (pt) artigo abrasivo , artigo revestido e método de formar um artigo abrasivo
MX2014000129A (es) Combinaciones de farmacos y su usos en el tratamiento de una condicion de tos.
BRPI0813456A2 (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para tratar um mamífero sofrendo de um distúrbio e de uma doença
PH12016500706B1 (en) Smoking article with liquid delivery material
EE05760B1 (et) Ravimkoostis
ITTO20110627A1 (it) Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche
BR112013015303A2 (pt) material de construção acústico empregando quitosana
BR112014029760A2 (pt) dispositivos de distribuição de agente bioativo e métodos para fazer e usar os mesmos
MX2016007534A (es) Composicion de gel de acido hialuronico que tiene durabilidad.
MY179519A (en) Smoking article with tactile liquid release component
WO2012142328A3 (en) Polymer microsphere compositions for localized delivery of therapeutic agents
MX2013013691A (es) Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
CY1123933T1 (el) Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης
BR112013005304A2 (pt) cosméticos de uso prolongado fixados e biofuncionais
RU2012144857A (ru) Способ доставки активных субстанций с помощью трансдермального пластыря, содержащего наноструктурированные везикулы кремнийорганической природы-ниосомы
MX2015008757A (es) Formulaciones de lorazepam de liberacion controlada.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]